Barriers to implementation of evidence-based electrical therapies and the need for outcome research: role of European registries.
Christian Wolpert,Andrzej Lubiński,Andrzej Bissinger,Béla Merkely,Silvia G. Priori,Josep Brugada +5 more
Reads0
Chats0
TLDR
The data based on European registries are useful for creating standards and harmonizing the treatment of arrhythmias and a summary of registry data can provide the opportunity to share and exchange information among ESC member countries on specific needs for improvements, reimbursement policy, and training issues.Abstract:
Although clinical trial results and the implementation of current guidelines appear to have encouraged progress in the treatment of arrhythmias, great discrepancies still exist between European Society of Cardiology (ESC) member countries. Guidelines are not adhered to for a variety of reasons. This cannot be explained only by economic factors, although these obviously play a substantial role. Other factors responsible for adequate guideline implementation appear to be the lack of trained personnel, the lack of infrastructure, or different health insurance systems. In this complex scenario, the data based on European registries are useful for creating standards and harmonizing the treatment of arrhythmias. Moreover, a summary of registry data, such as presented in the European Heart Rhythm Association (EHRA) White Book, can provide the opportunity to share and exchange information among ESC member countries on specific needs for improvements, reimbursement policy, and training issues.read more
Citations
More filters
Journal ArticleDOI
A Decade of Information on the Use of Cardiac Implantable Electronic Devices and Interventional Electrophysiological Procedures in the European Society of Cardiology Countries: 2017 Report from the European Heart Rhythm Association.
M J Pekka Raatikainen,David O. Arnar,Béla Merkely,Jens Cosedis Nielsen,Gerhard Hindricks,Hein Heidbuchel,John Camm +6 more
TL;DR: It was encouraging to note that during the past decade the growth in invasive arrhythmia therapies was greatest in the areas historically with relatively low activity, Nevertheless, there is substantial disparity and continued efforts are needed to improve harmonization of cardiac arrhythmmia therapies in the ESC area.
Journal ArticleDOI
Barriers to evidence‐based medicine: a systematic review
TL;DR: There are many barriers to the implementation and use of EBM and identifying barriers is just the first step to removing barriers, so extra resources will be needed if these barriers are to be tackled.
Journal ArticleDOI
Statistics on the use of cardiac electronic devices and electrophysiological procedures in the European Society of Cardiology countries: 2014 report from the European Heart Rhythm Association
M.J. Pekka Raatikainen,David O. Arnar,Katja Zeppenfeld,José L. Merino,Francisco Levya,Gerhardt Hindriks,Karl-Heinz Kuck +6 more
TL;DR: These statistics indicate that despite significant improvements, there still is considerable heterogeneity in the availability of arrhythmia therapies across the ESC area.
Journal ArticleDOI
Frequency and Determinants of Implantable Cardioverter Defibrillator Deployment Among Primary Prevention Candidates With Subsequent Sudden Cardiac Arrest in the Community
Kumar Narayanan,Kyndaron Reinier,Audrey Uy-Evanado,Carmen Teodorescu,Harpriya Chugh,Eloi Marijon,Karen Gunson,Jonathan Jui,Sumeet S. Chugh +8 more
TL;DR: The prevalence rates and influencing factors for deployment of primary prevention implantable cardioverter defibrillators (ICDs) among subjects who eventually experience sudden cardiac arrest in the general population have not been evaluated as discussed by the authors.
Journal ArticleDOI
Health technology assessment in interventional electrophysiology and device therapy: a position paper of the European Heart Rhythm Association.
Giuseppe Boriani,Nikos Maniadakis,Angelo Auricchio,Falk Müller-Riemenschneider,Falk Müller-Riemenschneider,Giovanni Fattore,Francisco Leyva,Lorenzo G. Mantovani,Lorenzo G. Mantovani,Markus Siebert,Stefan N. Willich,Panos E. Vardas,Paulus Kirchhof +12 more
TL;DR: This position paper reviews a series of issues that are related to HTAs for catheter ablation and device therapy and that in this view deserve attention.
References
More filters
Journal ArticleDOI
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Arthur J. Moss,Wojciech Zareba,W. Jackson Hall,Helmut U. Klein,David J. Wilber,David S. Cannom,James P. Daubert,Steven L. Higgins,Mary W. Brown,Mark L. Andrews +9 more
TL;DR: In patients with a prior myocardial infarction and advanced left ventricular dysfunction, prophylactic implantation of a defibrillator improves survival and should be considered as a recommended therapy.
Journal ArticleDOI
Amiodarone or an implantable cardioverter-defibrillator for congestive Heart failure
Gust H. Bardy,Kerry L. Lee,Daniel B. Mark,Jeanne E. Poole,Douglas L. Packer,Robin Boineau,Michael J. Domanski,Charles Troutman,Jill Anderson,Steven McNulty,Nancy E. Clapp-Channing,Linda Davidson-Ray,Elizabeth S. Fraulo,Daniel P. Fishbein,Richard M. Luceri,John Ip +15 more
TL;DR: In patients with NYHA class II or III CHF and LVEF of 35 percent or less, amiodarone has no favorable effect on survival, whereas single-lead, shock-only ICD therapy reduces overall mortality by 23 percent.
Journal ArticleDOI
Guidelines for the management of atrial fibrillation The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)
A. John Camm,Paulus Kirchhof,Irene Savelieva,Isabelle C. Van Gelder,Gerhard Hindricks,Ottavio Alfieri,Johan De Sutter,Andreas Goette,Stefan H. Hohloser,Piotr Ponikowski,Frans H. Rutten +10 more
TL;DR: Estimates of expected health outcomes for larger societies are included, where data exist, and the level of evidence and the strength of recommendation of particular treatment options are weighed and graded according to pre-defined scales.
Journal ArticleDOI
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Michael R. Bristow,Leslie A. Saxon,John P. Boehmer,Steven K. Krueger,David A. Kass,Teresa De Marco,Peter E. Carson,Lorenzo DiCarlo,David L. DeMets,Bill G. White,Dale W DeVries,Arthur M. Feldman +11 more
TL;DR: In this paper, the authors tested the hypothesis that prophylactic cardiac-resynchronization therapy in the form of biventricular stimulation with a pacemaker with or without a defibrillator would reduce the risk of death and hospitalization among patients with advanced chronic heart failure and intraventricular conduction delays.
Journal ArticleDOI
Guidelines for the management of atrial fibrillation
A. John Camm,Paulus Kirchhof,Gregory Lip,Ulrich Schotten,Irene Savelieva,Sabine Ernst,Isabelle C. Van Gelder,Nawwar Al-Attar,Gerhard Hindricks,Bernard Prendergast,Hein Heidbuchel,Ottavio Alfieri,Annalisa Angelini,Dan Atar,Paolo Colonna,Raffaele De Caterina,Johan De Sutter,Andreas Goette,Bulent Gorenek,Magnus Heldal,Stefan H. Hohloser,Philippe Kolh,Jean-Yves Le Heuzey,Piotr Ponikowski,Frans H. Rutten,Alec Vahanian,Angelo Auricchio,Jeroen J. Bax,Claudio Ceconi,Veronica Dean,Gerasimos Filippatos,Christian Funck-Brentano,Richard Hobbs,Peter Kearney,Theresa McDonagh,Bogdan A. Popescu,Zeljko Reiner,Udo Sechtem,Per Anton Sirnes,Michal Tendera,Panos E. Vardas,Petr Widimsky,Vazha Agladze,Etienne Aliot,Tosho L. Balabanski,Carina Blomström-Lundqvist,Alessandro Capucci,Harry J.G.M. Crijns,Björn Dahlöf,Thierry Folliguet,Michael Glikson,Marnix Goethals,Dietrich C. Gulba,Siew Yen Ho,Robert J.M. Klautz,Sedat Kose,John McMurray,Pasquale Perrone Filardi,Pekka Raatikainen,Maria Jesus Salvador,Martin J. Schalij,Alexander Shpektor,João de Sousa,Janina Stepinska,Hasso Uuetoa,José Luis Zamorano,Igor Zupan +66 more
TL;DR: Guidelines summarize and evaluate all currently available evidence on a particular issue with the aim of assisting physicians in selecting the best management strategy for an individual patient suffering from a given condition, taking into account the impact on outcome, as well as the risk–benefit ratio of particular diagnostic or therapeutic means.